DDW reports on some key news releases that emerged out of this year’s SLAS Europe. Cenevo reinforces agentic AI approach with new AI-assistant Announced at SLAS Europe, lab management specialist Cenevo launched a new AI-enabled capability for its agentic AI platform Mosaic. The company’s Mosaic AI Inventory Search enables scientists to search inventory… Read More
This article is sponsored by BMG Labtech. High-throughput screening (HTS) is predominantly used in drug discovery and relevant to the pharmaceutical industry as well as academic core facilities. With HTS, researchers can quickly test large libraries of chemical, biochemical, or pharmacological samples for drug candidates. Read More
This paid-for advertorial by BMG Labtech appeared in DDW Volume 25 – Issue 2, Spring 2024. Cannabinoid research has gained significant attention in recent years, as scientists have been exploring the potential therapeutic benefits of these compounds. From studying their role in treating neurological disorders to pain management, this field of… Read More
This paid-for advertorial by Aurora Microplates appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 Aurora Microplates is focused on making the highest quality, highest performing microplates available. The company uses the best materials, the cleanest and most precise moulding operations and facilities to deliver high performance microplates in… Read More
We know there are operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is slow and expensive, with high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the current pandemic is prompting a… Read More
Research laboratories have not fundamentally changed since the 1960s, says BMG LABTECH. Despite improvements in technology such as high-throughput screening and computational drug design, drug discovery is becoming slower and more expensive over time. Covid-19 highlighted operational vulnerabilities which are driving a fundamental reassessment of strategic priorities. In fact, says… Read More
Covid-19 has highlighted the current operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is still a slow and expensive process, with far too high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval,… Read More
